β受体阻滞剂/地尔硫治疗扩张型心肌病患者病死率的Meta分析

魏晶晶; 袁璟; 汪朝晖; 廖玉华

doi:10.13201/j.issn.1001-1439.2017.02.007

β受体阻滞剂/地尔硫治疗扩张型心肌病患者病死率的Meta分析

- 华中科技大学同济医学院附属协和医院心血管病研究所教育部生物靶向治疗研究重点室(武汉, 430022)

详细信息

通讯作者: 廖玉华,E-mail:liaoyh27@163.com

中图分类号: R542.2

收稿日期: 2016-12-12

Meta-analysis of efficacy of beta-blockers/diltiazem on mortality in patients with dilated cardiomyopathy

- Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: LIAO Yuhua, E-mail: liaoyh27@163.com

Received Date: 12 December 2016

摘要

摘要: 目的:应用Meta分析系统评价β受体阻滞剂/地尔硫䓬对扩张型心肌病(DCM)患者病死率的影响。方法:在PubMed、Elsevier、万方、知网数据库检索截止到2016-11-30有关β受体阻滞剂/地尔硫䓬治疗DCM患者病死率评价的临床研究(RCT或高质量前瞻性队列研究),按照Cochrance handbook提供的方法对纳入的RCT文献进行质量评估,前瞻性队列研究采取Newcastle-Ottawa Scale(NOS)评分进行质量评估,并提取相关数据,应用RevMan 5.3软件进行统计分析。结果:纳入7篇研究,共包含1 024例研究对象,其中4篇有关β受体阻滞剂,3篇有关地尔硫䓬。试验组共521例,对照组503例。平均随访时间7.4~36.0个月。汇总结果提示与对照组相比,β受体阻滞剂可降低全因死亡率[风险比(RR)＝0.61,95%可信区间(CI):0.43~0.85];同样地尔硫䓬也可降低全因死亡率(RR=0.42,95%CI:0.24~0.74)。结论:Meta分析结果提示β受体阻滞剂和地尔硫䓬均可降低DCM患者的全因死亡率,获益可能与药物抑制抗心肌抗体引起心肌细胞损伤和室性心律失常有关。
- β受体阻滞剂 /
- 地尔硫 /
- 抗心肌抗体 /
- 扩张型心肌病
Abstract: Objective:The purpose of this meta-analysis was to evaluate the efficacy of Beta-blockers/diltiazem on mortality in patients with dilated cardiomyopathy.Method:We searched in PubMed, Elsevier, WanFang and CNKI database, and found the randomized control trials or high quality prospective cohort studies about efficacy of Beta-blockers / diltiazem on mortality in patients with dilated cardiomyopathy. The quality of randomized control trials were assessed according to the method provided by the Cochrane Handbook. Newcastle-OttawaScale (NOS) score was evaluated in the quality of prospective cohort studies. Data were extracted and analyzed by using the Software RevMan 5.3. Result:In the 7 studies, 4 of them were Beta-Blockers studies and 3 were diltiazem researches. A total of 1 024 subjects, 521 of them were in the experimental group and 503 in the control group. The mean follow-up times were from 7.4 months to 36 months. Compared with placebo,Beta-blockers significantly reduced all cause mortality [random effect odds ratio (RR)=0.61, 95%confidence interval(CI):0.43 to 0.85] and diltiazem significantly reduced all cause mortality (RR=0.42, 95%CI:0.24 to 0.74). Conclusion:Meta-analysis suggests that Beta blockers and diltiazem can reduce all-cause mortality in patients with dilated cardiomyopathy, because they inhibit myocardial injury and ventricular arrhythmia caused by anti myocardial antibody.
- adrenergic beta-antagonists /
- diltiazem /
- anti myocardial antibody /
- dilated cardiomyopathy

HTML全文

参考文献(14)

[1]	廖玉华,涂源淑.器官特异性抗心肌自身抗体与扩张型心肌病[J].临床心血管病杂志,1992,8(4):255-257.
[2]	LIAO Y H,CHENG L X,DAI S P,et al.Autoantibodies against ADP/ATP carrier from patients with dilated cardiomyopathy increase activity of voltage-dependent Ca channels in isolated cardiac myocytes[J].Blood Pressure Suppl,1996,3:41-44.
[3]	LIAO Y H,CHENG L X,TU Y S,et al.Mechanism of anti-β-adrenoceptor antibody mediated myocardial damage in dilated cardiomyopathy[J].Tongji Med Univ,1997,17:5-8.
[4]	XIAO H,WANG M,DU Y,et al.Arrhythmogenic autoantibodies against calcium channel lead to sudden death in idiopathic dilated cardiomyopathy[J].Eur J Heart Fail,2011,13:264-270.
[5]	谷晓莹,余淼,廖玉华,等.抗心肌抗体对中国扩张型心肌病诊断价值的Meta分析[J].临床心血管病杂志,2016,32(10):1030-1038.
[6]	刘鸣.系统评价、meta-分析设计与实施方法[M].7版.北京:人民卫生出版社,2014:72-73.
[7]	SWEDBERG K,HJALMARSON A,WAAGSTEIN F,et al.Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade[J].Lancet,1979,313:1374-1376.
[8]	ANDERSON J L,LUTZ J R,GILBERT E M,et al.A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy[J].Am J Cardiol,1985,55:471-475.
[9]	WAAGSTEIN F,BRISTOW M R,SWEDBERG K,et al.Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Metoprolol in Dilated Cardiomyopathy(MDC)Trial Study Group[J].Lancet,1993,342:1441-1446.
[10]	薛树仁,张学禹,王敬平,等.美托洛尔对疗效的观察[J].中华心血管病杂志,2000,28(3):200-202.
[11]	FIGULLA H R,RECHENBERG J V,WIEGAND V,et al.Beneficial effects of long-term diltiazem treatment in dilated cardiomyopathy[J].J Am Coll Cardiol,1989,13:653-658.
[12]	FIGULLA H R,GIETZEN F,ZEYMER U,et al.Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy.Results of the Diltiazem in Dilated Cardiomyopathy Trial[J].Circulation,1996,94:346-352.
[13]	LIAO Y H.Interventional study of diltiazem in dilated cardiomyopathy:a report of multiple centre clinical trial in China.Chinese Cooperative Group of Diltiazem Intervention Trial in Dilated Cardiomyopathy[J].Int J Cardiol,1998,64:25-30.
[14]	魏晶晶,廖玉华.3类降脂药调节LDL-C代谢的meta分析[J].临床心血管病杂志,2016,32(9):894-900.